Niti Aayog Proposes Model Pharmaceutical Chapter for Future FTA Negotiations
Niti Aayog has recommended drafting a standardized pharmaceutical chapter for all future Free Trade Agreements to improve market access, streamline regulatory compliance, and support growth in high-value biopharma segments, encouraging a transition from generic-heavy exports toward innovation-driven manufacturing.
Highlights
- •Niti Aayog recommends a standard pharmaceutical chapter for all future FTA negotiations.
- •The proposed model aims to reduce compliance costs and address non-tariff trade barriers.
- •India seeks to increase focus on high-value sectors like biologics and biosimilars.
- •Current R&D investment by domestic firms trails behind international benchmarks of 15-20 percent.
In a significant policy recommendation, Niti Aayog has advocated for the creation of a standardized pharmaceutical chapter to be integrated into all future Free Trade Agreement (FTA) negotiations. The proposal aims to foster greater consistency in international trade discussions, improve market access for domestic players, and effectively dismantle persistent non-tariff barriers that currently hinder the global pharmaceutical trade.
Standardizing Global Pharmaceutical Trade
While various existing trade agreements already incorporate provisions related to the pharmaceutical sector, their practical benefits have often remained limited, as many clauses are primarily cooperative rather than mandatory. Although the recently concluded India-EU FTA took a positive step by including specific regulatory cooperation clauses, Niti Aayog emphasizes that such frameworks must become a standard feature across all upcoming trade pacts.
The proposed model pharmaceutical chapter is envisioned to serve as a comprehensive blueprint for both bilateral and multilateral negotiations. Key elements recommended for inclusion in this template are regulatory reliance frameworks, cooperation on intellectual property, Good Manufacturing Practice (GMP) inspections, streamlined product registration, standard harmonization, and transparent dispute-resolution mechanisms. By implementing these measures, the government seeks to significantly reduce compliance costs while enhancing regulatory predictability for exporters operating in key global markets.
Addressing R&D and Manufacturing Challenges
Currently, the nation’s pharmaceutical exports are heavily concentrated in volume-driven generic formulations. Participation in high-value, high-growth segments such as biologics, biosimilars, vaccines, and advanced therapeutic products remains relatively limited. These complex biomanufacturing facilities demand substantial capital expenditure, creating long-term investment hurdles for many companies.
The introduction of the Mission Biopharma SHAKTI scheme in 2026-27 is a vital initiative designed to stimulate local manufacturing of these advanced products. However, Niti Aayog suggests that a more comprehensive, long-term policy framework is necessary to ensure sustained technological development and industrial scale-up.
Furthermore, research and development in the pharmaceutical industry is inherently high-risk, characterized by long gestation periods. On a global scale, the sector ranks as the second-largest investor in R&D, often requiring 10 to 15 years for the development of a single new drug. Currently, domestic firms invest approximately 7 percent of their net sales into research, a figure that lags behind the 15 to 20 percent investment seen among international competitors. To bridge this gap, there is an urgent requirement for long-term funding mechanisms and strategic incentives to encourage the creation of new products and cutting-edge technologies.
